 Mitogen-Activated Protein Kinase Kinases
"Mitogen-Activated Protein Kinase Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A serine-threonine protein kinase family whose members are components in protein kinase cascades activated by diverse stimuli. These MAPK kinases phosphorylate MITOGEN-ACTIVATED PROTEIN KINASES and are themselves phosphorylated by MAP KINASE KINASE KINASES. JNK kinases (also known as SAPK kinases) are a subfamily.
| Descriptor ID |
D020929
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.565 D08.811.913.696.620.682.725.200 D12.644.360.440 D12.776.476.440
|
| Concept/Terms |
Mitogen-Activated Protein Kinase Kinases- Mitogen-Activated Protein Kinase Kinases
- Mitogen Activated Protein Kinase Kinases
- MAPKK
- MAPKKs
- MAP Kinase Kinases
- Kinase Kinases, MAP
- Kinases, MAP Kinase
- MAPK Kinases
- Kinases, MAPK
- Map Kinase Kinase
- Kinase Kinase, Map
- Kinase, Map Kinase
MAPK-ERK Kinases- MAPK-ERK Kinases
- Kinases, MAPK-ERK
- MAPK ERK Kinases
- MEKs
- MAP-ERK Kinase
- Kinase, MAP-ERK
- MAP ERK Kinase
|
Below are MeSH descriptors whose meaning is more general than "Mitogen-Activated Protein Kinase Kinases".
Below are MeSH descriptors whose meaning is more specific than "Mitogen-Activated Protein Kinase Kinases".
This graph shows the total number of publications written about "Mitogen-Activated Protein Kinase Kinases" by people in this website by year, and whether "Mitogen-Activated Protein Kinase Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 0 | 3 | 3 | | 1993 | 0 | 3 | 3 | | 1994 | 0 | 2 | 2 | | 1995 | 0 | 3 | 3 | | 1996 | 1 | 3 | 4 | | 1997 | 4 | 3 | 7 | | 1998 | 5 | 2 | 7 | | 1999 | 6 | 3 | 9 | | 2000 | 3 | 4 | 7 | | 2001 | 3 | 4 | 7 | | 2002 | 2 | 7 | 9 | | 2003 | 3 | 4 | 7 | | 2004 | 2 | 3 | 5 | | 2005 | 0 | 3 | 3 | | 2006 | 0 | 1 | 1 | | 2007 | 0 | 2 | 2 | | 2010 | 1 | 0 | 1 | | 2011 | 0 | 2 | 2 | | 2012 | 1 | 2 | 3 | | 2013 | 1 | 0 | 1 | | 2015 | 0 | 3 | 3 | | 2016 | 0 | 1 | 1 | | 2019 | 1 | 1 | 2 | | 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Mitogen-Activated Protein Kinase Kinases" by people in Profiles.
-
Min M, Rong Y, Tian C, Spencer SL. Temporal integration of mitogen history in mother cells controls proliferation of daughter cells. Science. 2020 06 12; 368(6496):1261-1265.
-
Kar A, Zhang Y, Yacob BW, Saeed J, Tompkins KD, Bagby SM, Pitts TM, Somerset H, Leong S, Wierman ME, Kiseljak-Vassiliades K. Targeting PDZ-binding kinase is anti-tumorigenic in novel preclinical models of ACC. Endocr Relat Cancer. 2019 10; 26(10):765-778.
-
Lewis KD, Larkin J, Ribas A, Flaherty KT, McArthur GA, Ascierto PA, Dréno B, Yan Y, Wongchenko M, McKenna E, Zhu Q, Mun Y, Hauschild A. Impact of depth of response on survival in patients treated with cobimetinib?±?vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. Br J Cancer. 2019 10; 121(7):522-528.
-
Goshen-Lago T, Goldberg-Carp A, Melamed D, Darlyuk-Saadon I, Bai C, Ahn NG, Admon A, Engelberg D. Variants of the yeast MAPK Mpk1 are fully functional independently of activation loop phosphorylation. Mol Biol Cell. 2016 09 01; 27(17):2771-83.
-
Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015 Sep; 21(9):1038-47.
-
Kumar D, Tewari-Singh N, Agarwal C, Jain AK, Inturi S, Kant R, White CW, Agarwal R. Nitrogen mustard exposure of murine skin induces DNA damage, oxidative stress and activation of MAPK/Akt-AP1 pathway leading to induction of inflammatory and proteolytic mediators. Toxicol Lett. 2015 Jun 15; 235(3):161-71.
-
Drasin DJ, Guarnieri AL, Neelakantan D, Kim J, Cabrera JH, Wang CA, Zaberezhnyy V, Gasparini P, Cascione L, Huebner K, Tan AC, Ford HL. TWIST1-Induced miR-424 Reversibly Drives Mesenchymal Programming while Inhibiting Tumor Initiation. Cancer Res. 2015 May 01; 75(9):1908-21.
-
Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol. 2013 May 10; 31(14):1767-74.
-
Kwong LN, Costello JC, Liu H, Jiang S, Helms TL, Langsdorf AE, Jakubosky D, Genovese G, Muller FL, Jeong JH, Bender RP, Chu GC, Flaherty KT, Wargo JA, Collins JJ, Chin L. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med. 2012 Oct; 18(10):1503-10.
-
Abdel-Hafiz HA, Horwitz KB. Control of progesterone receptor transcriptional synergy by SUMOylation and deSUMOylation. BMC Mol Biol. 2012 Mar 22; 13:10.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|